Merck begins trial of molnupiravir for COVID-19 with high risk of disease progression

by
Contributor since / Followers

3 weeks ago

Merck (NYSE:MRK) and partner Ridgeback Therapeutics have started a phase 3 trial examining its antiviral Lagevrio (molnupiravir) to treat adults with COVID-19 at high risk for disease progression.
The double-blind, placebo-controlled trial will only enroll individuals who have COVID-19 symptoms for

Tags: PFE